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Abstract The series of new acetylenic thioquinolines
containing propargyl, 4-chloro-2-butynyl, and 4-acyloxy-2-
butynyl groups have been prepared and tested for anti-
proliferative activity in vitro against human [SW707
(colorectal adenocarcinoma), CCRF/CEM (leukemia),
T47D (breast cancer)] and murine [P388 (leukemia), B16
(melanoma)] cancer lines. Most of the obtained compounds
exhibited antiproliferative activity, especially compounds
8, 12, and 21 showed the ID50 values ranging from 0.4 to
3.8 lg/ml comparable to that of cisplatin used as reference
compounds.
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Introduction
The carbon–carbon triple bond is one of the most important
functional groups in organic chemistry and pharmacology.
The structure activity relationship studies suggest that
introduction of alkyne motif may signiﬁcantly modify the
chemical, physical, and biological properties of acetylenic
compounds (Ben-Zvi and Danon, 1994). Among a large
group of synthetic and natural acetylenic compounds the
quinolines possessing an alkynyl moieties are of particular
interest as many of them display important activities,
namely antimicrobiological, anticancer, antiprotozoal, and
antiretroviral (Fuita et al., 1998; Fakhfakh et al., 2003;
Abele et al., 2002). Several acetylenic 2,5-disubstituted
decahydroquinoline alkaloids of wide spectra biological
activities have been isolated from the skins of frogs, toads
and related amphibians (Spande et al., 1999; Michael,
2000). It should be noted that less information is available
concerning the synthesis and biological evaluation of
alkynylthioquinolines (Abele et al., 2002; Makisumi and
Murabayashi, 1969; Boryczka, 1999). It is noteworthy that
no data about the synthesis and cytotoxic activity of
quinolines containing a selenoacetylenic substituent are
available. The chemical and physical properties of sele-
nium are very similar to those of sulfur but the biochem-
istry differs in at least two respects that distinguish them in
biological systems (Aboul-Faddl, 2005). First, in biological
systems selenium compounds are metabolized to more
reduced states, whereas sulfur compounds are metabolized
to more oxidized states; second, selenols are more acidic
than thiols, and they are readily oxidized. In general,
organoselenium compounds are more reactive than their
sulfur analogs due to weaker C–Se bond than the C–S
bond. These properties can be involved in higher activity of
the Se compounds against cancer cells than S derivatives
(Aboul-Faddl, 2005).
The synthetic methods for preparation of acetylenic
compounds are of interest especially with regard to the
synthesis of enediyne antitumor antibiotics or similar
molecules (Nicolaou and Dai, 1991; Grissom et al., 1996;
Joshi et al., 2007; Kumar et al., 2001). Several cyclic and
acyclic models have recently been developed, some of
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RESEARCHthem including pyridine and quinoline units (Rawat et al.,
2001; Knoll et al., 1988; Bhattacharyya et al., 2006).
We have reported a simple and efﬁcient method for the
synthesis of 3,4-disubstituted thioquinolines, which possess
one or two the same or different O, S, Se acetylenic groups.
The new acetylenic thioquinolines exhibited antiprolifera-
tive activity in vitro against a broad panel of human and
murine cancer cell lines comparable to cisplatin (Boryczka
et al., 2002a, 2002b;M o ´l et al., 2006, 2008). The struc-
ture–activity relationships study show a signiﬁcant corre-
lation between the antiproliferative activity and the
electronic properties expressed as
13C NMR chemical shift,
lipophilicity, and molecular electrostatic potential (Bor-
yczka et al., 2002b, 2003; Bajda et al., 2007; Boryczka
et al., 2010).
It is well known that several acetylenic compounds
possessing 2-butynyl motif exhibit speciﬁc pharmacologi-
cal activities, although the exact role of the 2-butynyl motif
in the activity of these derivatives is not fully understood
(Ben-Zvi and Danon, 1994).
As an extension of our work on the development of anti-
cancer drugs, we synthesized derivatives 6–12 and 16–25
with the aim to obtain more information about the inﬂuence
of 4-chloro-2-butynyl and 4-acyloxy-2-butynyl groups on
antiproliferative activity in this class of compounds.
Results and discussion
Chemistry
The synthesis of acetylenic thioquinolines 7–12 (Scheme 2)
was accomplished starting with 4-chloro-3-methylthioqui-
noline 3 or 4-chloro-3-propargyl-thioquinoline 4 or4-chloro-
3-(4-hydroxy-2-butynylthio)quinoline 5.
Compounds 3–5 were prepared according to our previ-
ously reported methods (Boryczka et al., 2002b;M o ´l et al.,
2008; Mas ´lankiewicz and Boryczka, 1993). 4-Chloro-
quinoline 6 was synthesized as shown in Scheme 1. The
starting 1 was prepared according to our published proce-
dure (Mas ´lankiewicz and Boryczka, 1993). Treatment of 1
with sodium methoxide in DMSO at 25C gave sodium
4-chloro-3-quinolinethiolate 1-A and 4-methoxy-3-methyl-
thioquinoline 2, which was removed by extraction. Sodium
salt 1-A after S alkylation using 1-bromo-4-chloro-2-
butyne gave 6 in 65% yield.
Compounds 3–5 were converted into 7–12 in 43–86%
yields by nucleophilic displacement of chlorine atom by
thiourea or selenourea in ethanol, hydrolysis of uronium
salt 3-A and subsequent S or Se alkylation of sodium salt
3-B with 1-bromo-4-chloro-2-butyne (Scheme 2).
In order to determine whether a acyloxy substituent at
C-4 of 2-butynyl group has any signiﬁcant inﬂuence on the
antiproliferative activity, new compounds bearing 4-acyl-
oxy-2-butynyl groups were prepared.
Thesynthesisofacetylenicthioquinolines16–25(Scheme 3)
was accomplished starting with 4-chloro-3-(4-hydroxy-2-
butynylthio)quinoline 5 or 4-(4-hydroxy-2-butynylthio)-3-
propargylthioquinoline13or4-(4-hydroxy-2-butynylseleno)-
3-methylthioquinoline 14 or 4-(4-hydroxy-2-butynylthio)-3-
methylthioquinoline15whichwerepreparedaccordingtoour
previously reported methods (Mo ´l et al., 2008).
The compounds 5 and 13–15 were converted into esters
16–25 with 42–91% yields by reactions with acylating
agents such as: o-phthalic anhydride, cinnamoyl chloride,
and benzoyl chloride or ethyl chloroformate in dry benzene
in the presence of pyridine.
The crude products were isolated from aqueous sodium
hydroxide by ﬁltration or extraction and separated by col-
umn chromatography.
Antiproliferative activity
The seventeen compounds were tested in SRB or MTT (in
the case of leukemia cells) assay for their antiproliferative
activity in vitro against three human cancer cell lines:
SW707 (colorectal adenocarcinoma), CCRF/CEM (leuke-
mia),T47D(breastcancer)andtwomurinecancercelllines:
P388 (leukemia), B16 (melanoma). The results of cytotoxic
activity in vitro were expressed as an ID50 (lg/ml), i.e., the
concentration of compound, which inhibits the proliferation
of 50% of tumor cells as compared to the control untreated
cells. Cisplatin was applied as a referential cytotoxic agent
(positive test control). A value of less than 4 lg/ml was
considered as an antiproliferative activity criterion for syn-
thetic compounds. The results of the cytotoxicity studies are
summarized in Table 1, previously reported data for com-
pounds 4-chloro-3-(4-hydroxy-2-butynylthio)-quinoline 5,
4-(4-hydroxy-2-butynylseleno)-3-methyl-thioquinoline 14
and 4-(4-hydroxy-2-butynylthio)-3-methylthioquinoline 15
were included for comparison (Mo ´l et al., 2008).
In general all the compounds 6–12 containing 4-chloro-
2-butynyl substituent exhibited a potent antiproliferative
activity against human and murine cancer lines applied.
4-Chloro-3-(4-chloro-2-butynylthio)quinoline 6 exhibited
high activity against SW707, CCRF/CEM, T47D, B16 and
moderate activity against P388. As reported previously
4-chloro-3-(4-hydroxy-2-butynylthio)quinoline 5 possessed
lower cytotoxic activity than 6 except activity against the
cells of P388 leukemia (Mo ´l et al., 2008).
In the series of derivatives 7–12, the replacement of
methyl group by propargyl or 4-hydroxy-2-butynyl, com-
pounds 9, 10 and 11, 12, respectively, resulted in decrease
of activity. Among compounds 7–12, the selenium deriv-
atives were more active than sulfur analogs and the
Med Chem Res (2011) 20:1402–1410 1403
123selenium compound 8 showed the most potent activity with
the ID50 values in the range 0.4–3.5 lg/ml against all
cancer lines applied.
Another noteworthy feature of the obtained compounds
results was the observation that leukemia (CCRF/CEM and
P388) and breast cancer (T47D) cells appear to be more
sensitive to the cytotoxic effects of the compounds 7–12
than two other cancer cells lines applied with ID50 value of
less than 4 lg/ml, which is considered as an antiprolifer-
ative activity criterion. It is important to note that the
compounds 7–12 exhibited higher cytotoxic activity
against breast cancer (T47D) cells than cisplatin.
The replacement of hydroxy group in 5 by hydroph-
thaloyloxy or cinnamoyloxy groups, compounds 16 and 17,
resulted in decrease of activity.
The substitution of hydroxy group in 4-(4-hydroxy-2-
butynylseleno)-3-methylthioquinoline 14 by hydrophtha-
loyloxy, benzoyloxy, and cinnamoyloxy, compounds 19,
21, and 24, respectively, resulted in decrease of activity
except activity against the cells of B16 melanoma. A
structure–activity relationships observed in compounds 19,
21, and 24 indicated that the rank order of cytotoxic
activity, against all cancer lines applied, according to the
nature of the acyloxy substituent is as follows:
benzoyloxy[hydrophthaloyloxy[cinnamoyloxy.
The replacement of hydroxy group in 4-(4-hydroxy-2-
butynylthio)-3-methylthioquinoline 15 by hydrophthaloyl-
oxy, cinnamoyloxy, benzoyloxy, or ethoxycarbonyloxy,
compounds 18, 20, 22, and 23, also resulted in the decrease
of activity. Comparing of compounds 18, 20, 22, and 23
indicated that the cytotoxic activity against SW707, CCRF/
CEM, T47D, and P388 were in the order ethoxycarbonyl-
oxy[hydrophthaloyloxy[cinnamoyloxy[benzoyloxy.
Whereas the activity of these compounds against B16 was
as follows: ethoxycarbonyloxy[cinnamoyloxy[ben-
zoyloxy[hydrophthaloyloxy. It is interesting to note that
the acyloxy compounds 16–25, prepared in this study,
exhibited the most potent cytotoxicity against cancer cell
B16 melanoma. These results may suggest that 4-acyloxy-
2-butynyl function is important for anti-melanoma activity.
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Scheme 1 Synthesis of
4-chloro-3-(4-chloro-2-
butynylthio)quinoline 6.
Reagents and conditions:
a MeONa, DMSO, 25C,
30 min; b 1-bromo-4-chloro-2-
butyne, NaOHaq, 25C, 30 min
12. R = CH2C CCH2OH, R' = CH2CC C H 2Cl,   X = Se
10. R = CH2C CH,            R' = CH2CC C H 2Cl,   X = Se
7. R=  CH 3,                        R' = CH2C CCH2Cl,    X = S
5. R = CH2C CCH2OH
4. R = CH2C CH
3. R = CH3
8. R = CH3,                        R' = CH2C CCH2Cl,   X = Se
9. R = CH2C CH,            R' = CH2CC C H 2Cl,   X = S
11. R = CH2C CCH2OH, R' = CH2CC C H 2Cl,   X = S
Cl-
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Scheme 2 Synthesis of acetylenic thioquinolines 7–12. Reagents and
conditions: a CS(NH2)2 or CSe(NH2)2, EtOH, 25C, 1 h; b NaOHaq,
c 1-bromo-4-chloro-2-butyne, NaOHaq, 25C, 30 min
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123Another noteworthy feature of the obtained results was the
observation that acyloxy compounds 19, 21, and 24
exhibited the most potent cytotoxicity with ID50 values
\3.1 lg/ml against B16 cancer cell line, among all the
compounds (5–25) prepared in this study. The replacement
of methyl group by propargyl, compounds 23 and 25,
respectively, resulted in decrease of activity.
Conclusions
Novel acetylenic thioquinolines 6–12 and 16–25, possess-
ing in positions 3 and 4, one or two, propargyl, 4-chloro-2-
butynyl, or 4-acyloxy-2-butynyl groups were synthesized
in good yields using 4-chloro-quinoline derivatives 3–5 and
4-hydroxy-2-butynyl derivatives 13–15 as starting mate-
rial. The obtained compounds were evaluated for antipro-
liferative activity in vitro against three human cancer cell
lines: SW707 (colorectal cancer), CCRF/CEM (leukemia),
T47D (breast cancer) and two murine cancer cell lines:
P388 (leukemia), B16 (melanoma). All the tested com-
pounds showed varied activity against different cancer cell
lines. As a result of the SAR, it was revealed that the nature
of the acetylenic substituent at the C-3 and C-4 positions
and character of the heteroatoms (Se and S) at C-4 criti-
cally inﬂuence the anticancer activity in vitro of the studied
compounds. Among the prepared compounds, 8, 12, and 21
were found to be the most active, with ID50 values ranging
from 0.4 to 3.8 lg/ml comparable to that of referential
anticancer drug, cisplatin. It is of interest to note that the
4-acyloxy-2-butynyl function is important for anti-mela-
noma activity. The obtained compounds seem to be good
candidate for further anticancer activity studies in vitro
using a broad panel of human and murine cell lines with the
aim to select compounds for studies in vivo.
Experimental
General techniques
Melting points were determined in open capillary tubes on
a Boetius melting point apparatus and are uncorrected.
1H
NMR (300 MHz) spectra were recorded on a Bruker MSL
300 spectrometer in CDCl3 solvents with tetramethylsilane
as internal standard; chemical shifts are reported in ppm (d)
and J values in Hz. Multiplicity is designated as singlet (s),
doublet (d), triplet (t), quartet (q), and multiplet (m). Mass
spectra were recorded under ?CI conditions on Finnigan
MAT 95 using isobutane as a reagent and temperature of
ion source of 200C. Elemental C, H, and N analyses were
obtained on a Carlo Erba Model 1108 analyzer. TLC was
R = CH3,             R' = COCH  CHC6H5, X = Se
25. R = CH2C CH, R' = COCH CHC6H5, X = S
24.
23. R = CH3,             R' = COCH CHC6H5, X =S
22. R = CH3,             R = COOC2H5,             X = S
21. R = CH3,             R' = COC6H5,               X = Se
20. R = CH3,             R' = COC6H5,               X = S 
19. R = CH3,             R' = COC6H4COOH,    X = Se
18. R = CH3,             R' = COC6H4COOH,    X = S 
17. R' = COCH CHC6H5
16. R' = COC6H4COOH
18-25
16-17
N
SR
XCH2CC C H 2OR'
N
Cl
SCH2C CCH2OR' a
15. R = CH3,             X = S
14. R = CH3,             X = Se
13. R = CH2C CH, X = S 
13-15
5
N
SR
XCH2CC C H 2OH
N
Cl
SCH2CC C H 2OH
b
Scheme 3 Synthesis of
acetylenic thioquinolines 16–25.
Reagents and conditions:
ao -phthalic anhydride or
cinnamoyl chloride, pyridine,
benzene, 70C, 1 h; bo -phthalic
anhydride or cinnamoyl
chloride or benzoyl chloride or
ethyl chloroformate, pyridine,
benzene, 70C, 1 h
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123Table 1 Structures of acetylenic thioquinolines 5–12, 14–25 and their antiproliferative activity in vitro and referential cisplatin against the cells
of human and murine cancer cell lines
Compound  Antiproliferative activity ID50 [µg/ml] 
e n i r u M n a m u H
SW707 CCRF/CEM  T47D  P388  B16 
5* 
N
Cl
SCH2CC C H 2OH
6.2±1.1 4.1±0.3  -  2.4±0.0 Neg 
6
N
Cl
SCH2CC C H 2Cl
3.3±0.3 3.7±1.5 3.2±2.0  13.4±12.2  4.0±0.5 
N
XR'
SR
RR ’ X
7 CH3 CH2CC C H 2Cl S 3.7±0.3  2.5±0.4  3.9±0.6  2.7±0.8 16.9±16.4 
8 CH3 CH2CC C H 2Cl Se 3.2±0.2 1.7±0.8 0.7±0.4  0.4±0.3  3.5±0.1 
9 CH2CC H CH2CC C H 2Cl S 12.9±8.2  2.9±0.3  5.8±1.3  3.0±1.1  52.8±3.8 
10  CH2CC H CH2CC C H 2Cl Se 3.2±0.2 1.8±1.5 0.4±0.1  0.8±0.7  7.1±3.1 
11  CH2C CCH2OH CH2CC C H 2Cl S 19.8±15.1  3.3±1.1  5.3±0.7  5.1±3.1  43.4±12.0 
12  CH2C CCH2OH CH2CC C H 2Cl Se 3.3±0.7 2.6±2.2 1.7±1.4  2.0±1.7  3.8±0.2 
14*  CH3 CH2CC C H 2OH Se 3.4±0.1  0.5±0.3  -  2.6±1.1  4.2±0.6 
15*  CH3 CH2CC C H 2OH S 34.9±7.6  2.3±0.7  -  3.1±0.2  49.8±0.5 
N
Cl
SCH2CC C H 2OR'
’ R
16  COC6H4COOH Neg Neg Neg  Neg  53.8±21.6 
17  COCH CHC6H5 48.8±4.6 15.4±9.9  22.8±22.3  32.8±23.4  11.4±9.7 
N
XCH2C
SR
CCH2OR'
RX ’ R
18  CH3 COC6H4COOH S 28.1±14.1  14.5±2.3  36.1±6.9  35.0±2.0  18.1±10.4 
19  CH3 COC6H4COOH Se 3.7±0.5 4.0±0.7 3.2±1.4  19.1±11.9  3.1±0.9 
20  CH3 COC6H5 S Neg  22.2±9.7  Neg  Neg  17.8±5.4 
21  CH3 COC6H5 Se 3.6±0.1  1.9±1.4  2.2±1.1 3.5±0.2 2.1±2.1 
22  CH3 COOC2H5 S 33.1±2.6  13.2±10.3  34.2±6.4  34.7±2.2  5.5±3.8 
23  CH3 COCH CHC6H5 S 66.6±2.7  18.1±9.1  71.9±16.7  Neg  9.4±8.2 
24  CH3 COCH CHC6H5 Se 4.7±0.5 17.8±17.4 4.3±0.9  43.9±18.9  3.1±1.3 
25  CH2CC H COCH CHC6H5 S Neg  50.9±35.1  Neg  Neg 14.7±16.5 
Cisplatin    6.0±0.3  1.5±0.2  6.7±1.3 1.7±0.2 4.7±0.2 
Neg Negative in the concentration used; * See ref. Mo ´l et al., 2008
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123performed on silica gel 60 254F plates (Merck) using a
mixture of chloroform and ethanol (15:1, v/v) as an eluent.
UV light and iodine accomplished visualization. Column
chromatography was performed on silica gel 60, \63 lm
(Merck) using a mixture of chloroform and ethanol (30:1,
v/v) as an eluent. Solvents were dried and puriﬁed
according to literature procedures.
Chemistry
The starting compounds: 4-chloro-30-methylthio-3,40-di-
quinolinyl sulﬁde 1 (Mas ´lankiewicz and Boryczka, 1993),
4-chloro-3-(methylthio)quinoline 3 (Mas ´lankiewicz and
Boryczka, 1993), 4-chloro-3-propargylthioquinoline 4 (Mo ´l
et al., 2006), 4-chloro-3-(4-hydroxy-2-butynylthio)quino-
line5(Mo ´letal.,2008),1-bromo-4-chloro-2-butyne(Bailey
and Fujiwara, 1955) were obtained according to methods
described previously.
Synthesis of 4-chloro-3-(4-chloro-2-butynylthio)
quinoline 6
A mixture of 4-chloro-30-methylthio-3,40-diquinolinyl sul-
ﬁde 1 (0.74 g, 2 mmol) and sodium methoxide (0.32 g,
6 mmol) in 8 ml DMSO was stirred at room temperature
for 30 min. The reaction mixture was poured into 20 ml of
5% aqueous sodium hydroxide and extracted with
4 9 5 ml of chloroform. The combined extracts were
washed with water, dried with anhydrous magnesium sul-
fate, and evaporated to give crude 2. To the water layer
1-bromo-4-chloro-2-butyne (0.33 g, 2 mmol) was added
and stirred for 30 min. The mixture was extracted with
4 9 5 ml of chloroform. The combined organic layer was
washed with water and dried with anhydrous magnesium
sulfate. After removal of the solvent the residue was
puriﬁed by column chromatography using chloroform/
ethanol (30:1) to give 0.37 g (65%) pure product 6: mp:
139–140C,
1H NMR (CDCl3) d: 3.82 (t, J = 2.4 Hz, 2H,
SCH2), 4.06 (t, J = 2.4 Hz, 2H, CH2Cl), 7.67–7.80 (m, 2H,
H-6 and H-7), 8.10–8.27 (m, 2H, H-5 and H-8), 8.98 (s, 1H,
H-2). CI MS m/z (rel. intensity) 286 (M ? 4, 10), 284
(M ? 2, 65), 282 (M, 100). Anal. Calc. for C13H9Cl2NS: C
55.33, H 3.21, N 4.96. Found: C 55.50, H 3.11, N 5.08.
General procedure for the synthesis of acetylenic
thioquinolines 7–12
A mixture of 4-chloro-3-methylthioquinoline 3 (0.42 g,
2 mmol) or 4-chloro-3-propargylthioquinoline 4 (0.45 g,
2 mmol) or 4-chloro-3-(4-hydroxy-2-butynylthio)quinoline
5 (0.50 g, 2 mmol) and selenourea (0.26 g, 2.1 mmol) or
thiourea (0.16 g, 2.1 mmol) in 99.8% ethanol (8 ml) was
stirred at room temperature for 1 h. The reaction mixture
was poured into 20 ml of 5% aqueous sodium hydroxide.
1-Bromo-4-chloro-2-butyne (0.38 g, 2.3 mmol) was added
dropwise to the aqueous layer, and the mixture was stirred
for 15 min. The resultant solid was ﬁltered off, washed
with water and air-dried to give crude products 7–12 which
were separated by column chromatography using chloro-
form/ethanol (30:1) to give pure products 7–12.
4-(4-Chloro-2-butynylthio)-3-methylthioquinoline (7) Yield
86%. Mp: 69–70C.
1H NMR (CDCl3, 300 MHz) d: 2.68
(s, 3H, SCH3), 3.73 (t, J = 2.1 Hz, 2H, CH2), 3.86 (t,
J = 2.1 Hz, 2H, CH2), 7.62–7.72 (m, 2H, H-6 and H-7),
8.11–8.59(m,2H,H-5andH-8),8.79(s,1H,H-2).CIMSm/
z (rel. intensity) 294 (M ? H
?, 100), 258 (40). Anal. Calc.
for C14H12ClNS2: C 57.23, H 4.12, N 4.77. Found: C 57.44,
H 4.05, N 4.80.
4-(4-Chloro-2-butynylseleno)-3-methylthioquinoline (8)
Yield 56%. Mp: 67–68C.
1H NMR (CDCl3, 300 MHz) d:
2.67 (s, 3H, SCH3), 3.62 (t, J = 2.4 Hz, 2H, CH2), 3.88 (t,
J = 2.4 Hz, 2H, CH2), 7.61–7.70 (m, 2H, H-6 and H-7),
8.14–8.52 (m, 2H, H-5 and H-8), 8.76 (s, 1H, H-2). CI MS
m/z (rel. intensity) 342 (M ? H
?, 100), 306 (35). Anal.
Calc. for C14H12ClNSSe: C 49.35, H 3.55, N 4.11. Found:
C 49.47, H 3.38, N 4.20.
4-(4-Chloro-2-butynylthio)-3-(propargylthio)quinoline (9)
Yield63%.Mp:109–110C.
1HNMR(CDCl3,300 MHz)d:
2.28(t,J = 2.7 Hz,1H,CH),3.74(t,J = 2,4 Hz,2H,CH2),
3.84 (d, J = 2.7 Hz, 2H, CH2S), 3.88 (t, J = 2.4 Hz, 2H,
CH2),7.65–7.72(m,2H,H-6andH-7),8.10–8.59(m,2H,H-
5 and H-8), 9.01 (s, 1H, H-2). CI MS m/z (rel. intensity) 318
(M ? H
?, 100), 282 (20), 232 (15). Anal. Calc. for
C16H12ClNS2: C 60.46, H 3.81, N 4.41. Found: C 60.67, H
3.90, N 4.30.
4-(4-Chloro-2-butynylseleno)-3-(propargylthio)quinoline
(10) Yield 77%. Mp: 92–93C.
1H NMR (CDCl3,
300 MHz) d: 2.28 (t, J = 2.7 Hz, 1H, CH), 3.63 (t,
J = 2.4 Hz, 2H, CH2), 3.82 (d, J = 2.7 Hz, 2H, CH2S),
3.89 (t, J = 2.4 Hz, 2H, CH2), 7.66–7.72 (m, 2H, H-6 and
H-7), 8.07–8.53 (m, 2H, H-5 and H-8), 8.99 (s, 1H, H-2).
CI MS m/z (rel. intensity) 366 (M ? H
?, 100), 326 (20).
Anal. Calc. for C16H12ClNSSe: C 52.69, H 3.32, N 3.84.
Found: C 52.77, H 3.40, N 3.68.
4-(4-Chloro-2-butynylthio)-3-(4-hydroxy-2-butynylthio)
quinoline (11) Yield 58%. Mp: 103–104C.
1HN M R
(CDCl3, 300 MHz) d: 3.75 (t, J = 2.1 Hz, 2H, CH2),
3.87–3.89 (m, 4H, 29 CH2), 4.24 (t, J = 2.1 Hz, 2H,
CH2), 7.66–7.74 (m, 2H, H-6 and H-7), 8.10–8.58 (m, 2H,
H-5 and H-8), 9.02 (s, 1H, H-2). CI MS m/z (rel. intensity)
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123348 (M ? H
?, 40), 362 (55), 244 (100). Anal. Calc. for
C17H14ClNOS2: C 58.70, H 4.06, N 4.03. Found: C 58.62,
H 4.15, N 3.86.
4-(4-Chloro-2-butynylseleno)-3-(4-hydroxy-2-butynylthio)
quinoline (12) Yield 43%. Mp: 99–100C.
1HN M R
(CDCl3, 300 MHz) d: 3.64 (t, J = 2.4 Hz, 2H, CH2),
3.86–3.89 (m, 4H, 29 CH2), 4.24 (t, J = 2.4 Hz, 2H,
CH2), 7.63–7.72 (m, 2H, H-6 and H-7), 8.06–8.49 (m, 2H,
H-5 and H-8), 8.97 (s, 1H, H-2). CI MS m/z (rel. intensity)
396 (M ? H
?, 44), 310 (90), 292 (100). Anal. Calc. for
C17H14ClNOSSe: C 51.72, H 3.57, N 3.55. Found: C 51.90,
H 3.65, N 3.42.
General procedure for the synthesis of acetylenic
thioquinolines 16–25
A mixture of 4-chloro-3-(4-hydroxy-2-butynylthio)quino-
line 5 (0.53 g, 2 mmol) or 4-(4-hydroxy-2-butynylthio)-
3-propargylthioquinoline 13 or (0.60 g, 2 mmol) 4-(4-
hydroxy-2-butynylseleno)-3-methylthioquinoline 14 (0.64 g,
2 mmol) or 4-(4-hydroxy-2-butynylthio)-3-methylthioquin-
oline 15 (0.55 g, 2 mmol) and pyridine (0.17 g, 2.1 mmol)
and (2.1 mmol) o-phthalic anhydride or cinnamoyl chloride
or benzoyl chloride or ethyl chloroformate in dry benzene
(8 ml) was stirred at 70C for about 1 h (monitored by TLC
until complete consumption of starting materials) and then
concentratedinvacuo.Theresiduewasseparatedbycolumn
chromatography using chloroform/ethanol (30:1) to give
pure products 16–25.
4-Chloro-3-(4-hydrophthaloyloxy-2-butynylthio)quinoline
(16) Yield 64%. Mp: 97–98C.
1H NMR (CDCl3,
300 MHz) d: 3.66 (t, J = 2.1 Hz, 2H, CH2), 4.81 (t,
J = 2.1 Hz, 2H, CH2), 7.31–7.64 (m, 6H, C6H4 and H-6
and H-7), 7.72–8.10 (m, 2H, H-5 and H-8), 8.29 (s, 1H, H-
2). CI MS m/z (rel. intensity) 412 (M ? H
?, 10), 246
(100). Anal. Calc. for C21H14ClNO4S: C 61.24, H 3.43, N
3.40. Found: C 61.42, H 3.50, N 3.31.
4-Chloro-3-(4-cinnamoyloxy-2-butynylthio)quinoline (17)
Yield 60%. Mp: 123–124C.
1H NMR (CDCl3, 300 MHz)
d: 3.84 (t, J = 2.1 Hz, 2H, CH2), 3.74 (t, J = 2.1 Hz, 2H,
CH2), 6.37 (d, J = 15.9 Hz, 1H, CH), 7.39–7.73 (m, 8H,
CH and C6H5 and H-6 and H-7), 8.07–8.23 (m, 2H, H-5
and H-8), 9.00 (s, 1H, H-2). CI MS m/z (rel. intensity) 394
(M ? H
?, 100). Anal. Calc. for C22H16ClNO2S: C 67.09,
H 4.09, N 3.56. Found: C 67.25, H 3.91, N 3.62.
4-(4-Hydrophthaloyloxy-2-butynylthio)-3-metylthioquino-
line (18) Yield 50%. Mp: 96–97C.
1H NMR (CDCl3,
300 MHz) d: 2.64 (s, 3H, SCH3), 3.61 (t, J = 2,1 Hz, 2H,
CH2), 4.63 (t, J = 2.1 Hz, 2H, CH2), 7.26–7.93 (m, 6H,
C6H4 and H-6 and H-7), 8.01–8.48 (m, 2H, H-5 and H-8),
8.85 (s, 1H, H-2). CI MS m/z (rel. intensity) 424 (M ? H
?,
10), 276 (100). Anal. Calc. for C22H17NO4S2: C 62.39, H
4.05, N 3.31. Found: C 62.55, H 4.10, N 3.22.
4-(4-Hydrophthaloyloxy-2-butynylseleno)-3-methylthio-
quinoline (19) Yield 52%. Mp: 126–127C.
1HN M R
(CDCl3, 300 MHz) d: 2.67 (s, 3H, SCH3), 3.51 (t,
J = 2.4 Hz, 2H, CH2), 4.68 (t, J = 2.4 Hz, 2H, CH2),
7.52–7.89 (m, 6H, C6H4 and H-6 and H-7), 8.09–8.40 (m,
2H, H-5 and H-8), 8.78 (s, 1H, H-2). CI MS m/z (rel.
intensity) 472 (M ? H
?, 5), 324 (100). Anal. Calc. for
C22H17NO4SSe: C 56.17, H 3.64, N 2.98. Found: C 56.29,
H 3.75, N 3.12.
4-(4-Benzoyloxy-2-butynylthio)-3-methylthioquinoline (20)
Yield 90%. Mp: 88–89C.
1H NMR (CDCl3, 300 MHz) d:
2.65 (s, 3H, SCH3), 3.74 (t, J = 2.1 Hz, 2H, CH2), 4.68 (t,
J = 2.1 Hz, 2H, CH2), 7.42–7.61 (m, 7H, C6H5 and H-6
and H-7), 8.15–8.59 (m, 2H, H-5 and H-8), 8.78 (s, 1H, H-
2). CI MS m/z (rel. intensity) 380 (M ? H
?, 100). Anal.
Calc. for C21H17NO2S2: C 66.47, H 4.52, N 3.69. Found: C
66.34, H 4.48, N 3.78.
4-(4-Benzoyloxy-2-butynylseleno)-3-methylthioquinoline
(21) Yield 54%. Mp: 92–93C.
1H NMR (CDCl3,
300 MHz) d: 2.64 (s, 3H, SCH3), 3.63 (t, J = 2.4 Hz, 2H,
CH2), 4.69 (t, J = 2.4 Hz, 2H, CH2), 7.42–7.99 (m, 7H,
C6H5 and H-6 and H-7), 8.05–8.54 (m, 2H, H-5 and H-8),
8.75 (s, 1H, H-2). CI MS m/z (rel. intensity) 428 (M ? H
?,
100). Anal. Calc. for C21H17NO2SSe: C 59.15, H 4.02, N
3.28. Found: C 58.94, H 4.15, N 3.34.
4-(4-Ethoxycarbonyloxy-2-butynylthio)-3-methylthioquino-
line (22) Yield 93%. Mp: 48–49C.
1H NMR (CDCl3,
300 MHz) d: 1.30 (t, J = 7.2 Hz, 3H, CH3), 2.68 (s, 3H,
SCH3), 3.70 (t, J = 2.4 Hz, 2H, CH2), 4.18 (q, J = 7.2 Hz,
2H, OCH2), 4.85 (t, J = 2.4 Hz, 2H, CH2), 7.61–7.73 (m,
2H, H-6 and H-7), 8.05–8.59 (m, 2H, H-5 and H-8), 8,79 (s,
1H, H-2). CI MS m/z (rel. intensity) 348 (M ? H
?, 100).
Anal. Calc. for C17H17NO3S2: C 58.77, H 4.93, N 4.03.
Found: C 58.98, H 4.85, N 4.19.
4-(4-Cinnamoyloxy-2-butynylthio)-3-methylthioquinoline
(23) Yield 91%. Mp: 82–83C.
1H NMR (CDCl3,
300 MHz) d: 2.68 (s, 3H, SCH3), 3.73 (t, J = 2.1 Hz, 2H,
CH2), 4.57 (t, J = 2.1 Hz, 2H, CH2), 6.36 (d, J = 16.2 Hz,
1H, CH), 7.39–7.68 (m, 8H, CH and C6H5 and H-6 and H-
7), 8.04–8.59 (m, 2H, H-5 and H-8), 8.80 (s, 1H, H-2). CI
MS m/z (rel. intensity) 406 (M ? H
?, 100). Anal. Calc. for
C23H19NO2S2: C 68.12, H 4.72, N 3.45. Found: C 68.32, H
4.56, N 3.48.
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1234-(4-Cinnamoyloxy-2-butynylseleno)-3-methylthioquino-
line (24) Yield 42%. Mp: 98–99C.
1H NMR (CDCl3,
300 MHz) d: 2.67 (s, 3H, SCH3), 3.63 (t, J = 2.1 Hz, 2H,
CH2), 4.58 (t, J = 2.1 Hz, 2H, CH2), 6.37 (d, J = 15.9 Hz,
1H, CH), 7.39–7.69 (m, 8H, CH and C6H5 and H-6 and H-
7), 8.02–8.53 (m, 2H, H-5 i H-8), 8.77 (s, 1H, H-2). CI MS
m/z (rel. intensity) 453 (M ? H
?, 90), 256 (100). Anal.
Calc. for C23H19NO2SSe: C 61.06, H 4.23, N 3.10. Found:
C 60.81, H 4.12, N 3.18.
4-(4-Cinnamoyloxy-2-butynylthio)-3-(propargylthio)quino-
line (25) Yield 80%. Mp: 102–103C.
1H NMR (CDCl3,
300 MHz) d: 2.27 (t, J = 2,7 Hz, 1H, CH), 3.75 (t,
J = 2,4 Hz, 2H, CH2), 3.84 (d, J = 2.7 Hz, 2H, SCH2),
4.58 (t, J = 2.4 Hz, 2H, CH2), 6.36 (d, J = 15.9 Hz, 1H,
CH), 7.39–7.69 (m, 8H, CH and C6H5 and H-6 and H-7),
8.07–8.60 (m, 2H, H-5 and H-8), 9.01 (s, 1H, H-2). CI MS
m/z (rel. intensity) 430 (M ? H
?, 20), 232 (100). Anal.
Calc. for C25H19NO2S2: C 69.90, H 4.46, N 3.26. Found: C
70.12, H 4.52, N 3.38.
Antiproliferative assay in vitro
Cells
The following established in vitro cancer cell lines were
applied: SW707 (human colorectal adenocarcinoma),
CCRF/CEM (human leukemia), T47D (human breast can-
cer), P388 (mouse leukemia), and B16 (mouse melanoma).
All lines were obtained from the American Type Culture
Collection (Rockville, Maryland, USA) and maintained at
the Cell Culture Collection of the Institute of Immunology
and Experimental Therapy, Wroclaw, Poland.
Twenty-four hours before addition of the tested agents,
the cells were plated in 96-well plate (Sarstedt, USA) at a
density of 10
4 cells per well in 100 ll of culture medium.
The cells were cultured in the opti-MEM medium supple-
mented with 2 mM glutamine (Gibco, Warsaw, Poland),
streptomycin (50 lg/ml), penicillin (50 U/ml) (both anti-
biotics from Polfa, Tarchomin, Poland), and 5% fetal calf
serum (Gibco, Grand Island, USA). The cell cultures were
maintained at 37C in humid atmosphere saturated with 5%
CO2.
SRB assay
The details of this technique were described by Skehan
et al. (1990). The cytotoxicity assay was performed after
72-h exposure of the cultured cells to varying concentra-
tions (from 0.1 to 100 lg/ml) of the tested agents. The
compounds were dissolved in 10% DMSO to concentration
of 1 mg/ml, and subsequently diluted in culture medium to
reach the required concentrations. DMSO, which was used
as a solvent did not exert any inhibitory effect on cell
proliferation. The cells attached to the plastic were ﬁxed by
gently layering cold 50% TCA (trichloroacetic acid,
Aldrich-Chemie, Germany) on the top of the culture
medium in each well. The plates were incubated at 4C for
1 h and then washed ﬁve times with tap water. The back-
ground optical density was measured in the wells ﬁlled
with culture medium, without the cells. The cellular
material ﬁxed with TCA was stained with 0.4% sulforho-
damine B (SRB, Sigma, Germany) dissolved in 1% acetic
acid (POCh, Gliwice, Poland) for 30 min. Unbound dye
was removed by rinsing (49) with 1% acetic acid. The
protein-bound dye was extracted with 10 mM unbuffered
tris base (POCh, Gliwice, Poland) for determination of
optical density (at 540 nm) in a computer-interfaced, 96-
well microtiter plate reader Multiskan RC photometer
(Labsystems, Helsinki, Finland). Each compound in given
concentration was tested in triplicates in each experiment,
which was repeated 3–5 times.
MTT assay
This technique was applied for the cytotoxicity screening
against mouse leukemia cells growing in suspension cul-
ture. An assay was performed after 72-h exposure to
varying concentrations (from 0.1 to 100 lg/ml) of the
tested agents. The compounds were dissolved in 10%
DMSO to concentration of 1 mg/ml, and subsequently
diluted in culture medium to reach the required concen-
trations. DMSO, which was used as a solvent did not exert
any inhibitory effect on cell proliferation. For the last
3–4 h of incubation 20 ll of MTT solution were added to
each well (MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide; stock solution: 5 mg/ml). The mito-
chondria of viable cells reduce the pale yellow MTT to a
navy blue formazan: the more viable cells are present in
well, the more MTT will be reduced to formazan. When
incubation time was completed, 80 ll of the lysing mixture
was added to each well (lysing mixture: 225 ml dimeth-
ylformamide, 67.5 g sodium dodecyl sulfate, and 275 ml
of distilled water). After 24 h, when formazan crystals had
been dissolved, the optical densities of the samples were
read on an Multiskan RC photometer at 570 nm
wavelength.
Each compound in given concentration was tested in
triplicates in each experiment, which was repeated 3–5
times.
The results of cytotoxic activity in vitro were expressed
as an ID50—the dose of compound (in lg/ml) that inhibits
proliferation rate of the tumor cells by 50% as compared to
the control untreated cells.
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